Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim

Introduction: Dipeptidyl Peptidase 4 Inhibitor (DPP4-I) is a relatively new antidiabetic agent, hence the study on glycemic outcome in Malaysian population is still lacking. Currently, there is no study conducted in Putrajaya Hospital to examine the outcome of DPP4-I and its combination on glycemic...

Description complète

Détails bibliographiques
Auteur principal: Noor Rahim, Nurhamizah
Format: Thèse
Langue:anglais
Publié: 2016
Sujets:
Accès en ligne:https://ir.uitm.edu.my/id/eprint/26211/1/TM_NURHAMIZAH%20NOOR%20RAHIM%20PH%2017_5.pdf
_version_ 1846217959222018048
author Noor Rahim, Nurhamizah
author_facet Noor Rahim, Nurhamizah
author_sort Noor Rahim, Nurhamizah
description Introduction: Dipeptidyl Peptidase 4 Inhibitor (DPP4-I) is a relatively new antidiabetic agent, hence the study on glycemic outcome in Malaysian population is still lacking. Currently, there is no study conducted in Putrajaya Hospital to examine the outcome of DPP4-I and its combination on glycemic control of Type 2 Diabetes Mellitus (T2DM) patients, response towards DPP4-I and predictors for HbA1c reduction. Objective: To evaluate outcome at week 16, 32 and 52; to determine ADR arises from DPP4-I; and to evaluate predictors for HbA1c reduction at week 52. Method: A retrospective observational study was conducted on 184 T2DM patients that were prescribed with DPP4-I. Paired t-test, ANOVA and linear regression analysis were conducted accordingly. Results: 39.1% of study subjects managed to attain HbA1c value ≤7.0% after 52 weeks of therapy with DPP4-I and its combinations. The mean HbA1c reduction was 0.7% compared to baseline. 70.7% were responsive to the DPP4-I treatment with age at the initiation of DPP4-I, mean HbA1c at baseline and week 52 and mean number of antidiabetics prescribed at baseline and week 52 were significantly different between subgroups. Unresponsive subgroup attained only 0.2% HbA1c reduction at around week 16 compared to significant HbA1c reduction attained by responsive group. 2.7% adverse drug reaction related to DPP4-I was reported. Baseline HbA1c values, HbA1c changes at around week 16 and age were found to be the predictors for HbA1c reduction. Conclusion: The addition of DPP4-I demonstrated moderate glycemic reduction to T2DM patients. However, factors such as adherence towards antidiabetics, diet, physical activity and insulin intensification that was not assessed in this study may also influence this effect.
format Thesis
id oai:ir.uitm.edu.my:26211
institution Universiti Teknologi MARA
language English
publishDate 2016
record_format eprints
spelling oai:ir.uitm.edu.my:262112019-11-28T09:50:34Z https://ir.uitm.edu.my/id/eprint/26211/ Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim Noor Rahim, Nurhamizah Specialties of internal medicine Diabetes Mellitus Introduction: Dipeptidyl Peptidase 4 Inhibitor (DPP4-I) is a relatively new antidiabetic agent, hence the study on glycemic outcome in Malaysian population is still lacking. Currently, there is no study conducted in Putrajaya Hospital to examine the outcome of DPP4-I and its combination on glycemic control of Type 2 Diabetes Mellitus (T2DM) patients, response towards DPP4-I and predictors for HbA1c reduction. Objective: To evaluate outcome at week 16, 32 and 52; to determine ADR arises from DPP4-I; and to evaluate predictors for HbA1c reduction at week 52. Method: A retrospective observational study was conducted on 184 T2DM patients that were prescribed with DPP4-I. Paired t-test, ANOVA and linear regression analysis were conducted accordingly. Results: 39.1% of study subjects managed to attain HbA1c value ≤7.0% after 52 weeks of therapy with DPP4-I and its combinations. The mean HbA1c reduction was 0.7% compared to baseline. 70.7% were responsive to the DPP4-I treatment with age at the initiation of DPP4-I, mean HbA1c at baseline and week 52 and mean number of antidiabetics prescribed at baseline and week 52 were significantly different between subgroups. Unresponsive subgroup attained only 0.2% HbA1c reduction at around week 16 compared to significant HbA1c reduction attained by responsive group. 2.7% adverse drug reaction related to DPP4-I was reported. Baseline HbA1c values, HbA1c changes at around week 16 and age were found to be the predictors for HbA1c reduction. Conclusion: The addition of DPP4-I demonstrated moderate glycemic reduction to T2DM patients. However, factors such as adherence towards antidiabetics, diet, physical activity and insulin intensification that was not assessed in this study may also influence this effect. 2016 Thesis NonPeerReviewed text en https://ir.uitm.edu.my/id/eprint/26211/1/TM_NURHAMIZAH%20NOOR%20RAHIM%20PH%2017_5.pdf Noor Rahim, Nurhamizah (2016) Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim. (2016) Masters thesis, thesis, Universiti Teknologi MARA.
spellingShingle Specialties of internal medicine
Diabetes Mellitus
Noor Rahim, Nurhamizah
Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
title Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
title_full Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
title_fullStr Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
title_full_unstemmed Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
title_short Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital / Nurhamizah Noor Rahim
title_sort outcome evaluation of dipeptidyl peptidase 4 dpp4 inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at putrajaya hospital nurhamizah noor rahim
topic Specialties of internal medicine
Diabetes Mellitus
url https://ir.uitm.edu.my/id/eprint/26211/1/TM_NURHAMIZAH%20NOOR%20RAHIM%20PH%2017_5.pdf
url-record https://ir.uitm.edu.my/id/eprint/26211/
work_keys_str_mv AT noorrahimnurhamizah outcomeevaluationofdipeptidylpeptidase4dpp4inhibitorsanditscombinationonglycemiccontroloftype2diabetesmellituspatientsatputrajayahospitalnurhamizahnoorrahim